Biotech ApS Wg is Director at Y-mAbs Therapeutics, Inc. (YMAB). They have made 10 open-market trades across 1 company since 2021, most recently 2025-09-16.
CIK 0001753193
5 open-market purchases totalling $4.4M since 2023, against 5 sales. Across 5 scored buys the stock is up 111.9% at ninety days, and 101.9 points ahead of the S&P over the same stretch.
5 scored purchases · one row per filing · discretionary only
| Ticker | Shares | Value |
|---|---|---|
| YMAB | 4,559,233 | $39.3M |
Shares reported on the most recent Form 4, priced at the 2023-12-12 close.
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 60% | 80% | 80% |
| Avg Move | -2.8% | +1.1% | +111.9% |
| Alpha | -4.9% | -2.9% | +101.9% |
| Scored | 5 | 5 | 5 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| YMAB | BUY | 2023-12-11 | 2023-12-12 | $6.85 | $44K | +0.3% | +11.2% | +143.6% |
| YMAB | BUY | 2023-12-07 | 2023-12-11 | $6.99 | $1.7M | -9.4% | +3.5% | +137.6% |
| YMAB | BUY | 2023-11-29 | 2023-12-01 | $5.97 | $619K | +8.6% | +8.9% | +164.7% |
| YMAB | BUY | 2023-11-27 | 2023-11-29 | $5.60 | $1.0M | +3.7% | +6.2% | +157.0% |
| YMAB | BUY | 2023-05-15 | 2023-05-17 | $9.65 | $982K | -17.4% | -24.4% | -43.1% |
| YMAB | SELL | 2021-06-10 | 2021-06-11 | $36.15 | $812K | -5.7% | -9.5% | -9.4% |
| YMAB | SELL | 2021-06-08 | 2021-06-10 | $35.99 | $5.4M | -9.5% | -12.6% | -15.1% |
| YMAB | SELL | 2021-06-07 | 2021-06-09 | $34.15 | $2.5M | +1.2% | -9.3% | -12.1% |
| YMAB | SELL | 2021-06-03 | 2021-06-07 | $33.28 | $2.3M | +7.3% | -9.1% | -9.0% |
| YMAB | SELL | 2021-05-28 | 2021-06-02 | $36.17 | $2.3M | +7.5% | +2.3% | -9.0% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.